BeStock  
Stocks › IOVA

Iovance Biotherapeutics IOVA

US equityMarket cap rank #2386
$6.90 −$0.41 (-5.61%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $6.99 +1.25%
Open$7.17
Prev close$7.31
Day range$6.77 – $7.40
Volume13.73M
Market cap$3.19B
P/E (TTM)–
Dividend yield–
Founded2007
CEODr. Frederick G. Vogt, J.D.
Employees975
HeadquartersSan Carlos, United States of America
Websitewww.iovance.com

Revenue per employee

$-19.3K$84.4K$188.0K$291.7KDec '23Dec '24Dec '25

975 employees as of 2025/FY (+16.3% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Daniel Gordon Kirby Chief Commercial Officer
Age 54 · Total comp. $2,160,594.00 · As of 27 Apr 2026
Background

Mr. Daniel Gordon Kirby joined the Company in February 2025 as our Chief Commercial Officer, bringing deep experience in commercial operations, including cell therapy. Prior to joining the Company, Mr. Kirby led global commercial strategy and operations for an emerging cell therapy platform of products as Chief Commercial Officer of Orca Bio. From 2018 to 2020, he served as Chief Commercial Officer at Omeros Corporation, overseeing U.S. and EU launch readiness for narsoplimab targeting complications post hematopoietic stem cell transplantation as well as all commercial activities for their marketed product, Omidria. Previously, he led market access, reimbursement and marketing efforts for CAR T products as Vice President and Head of U.S. Cell and Gene at Celgene (now Bristol-Myers Squibb). He joined Celgene following the acquisition of Juno Therapeutics, where he was Vice President of Marketing and Market Access. Earlier in his career, Mr. Kirby was Head of Marketing for Medivation (now Pfizer) and held various commercial roles of increasing responsibility during a 14-year tenure at Amgen. He holds a B.A. from the University of Maryland.

Dr. Frederick G. Vogt, J.D. Director, General Counsel, Interim Chief Executive Officer and President
Age 52 · Total comp. $1,888,175.00 · As of 27 Apr 2026
Background

Dr. Frederick G. Vogt, J.D. became our Interim Chief Executive Officer and President on June 10, 2021, and became our General Counsel on July 1, 2017. He originally joined the Company in September 2016, and has 25 years of experience in the pharmaceutical and biopharmaceutical industries. Over more than eight years with the Company, Dr. Vogt has led our construction of the Iovance Cell Therapy Center (the iCTC), acquisition of Proleukin, and approval and launch of Amtagvi, among other major accomplishments. Prior to joining Iovance, Dr. Vogt practiced law at the international firm of Morgan, Lewis & Bockius LLP, focusing on intellectual property and business law in the life sciences and representing clients in patent strategy, transactional, and litigation matters. Previously he served in numerous scientific, management, and legal roles of increasing responsibility over a period of 13 years at GlaxoSmithKline, where he focused primarily on oncology and cardiovascular drug development. While at GSK, Dr. Vogt made contributions to the development and approval of Hycamtin, Votrient, Tafinlar, and Mekinist. Dr. Vogt holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from the Pennsylvania State University, and a J.D. from Temple University. He has authored or co-authored more than 70 research papers and book chapters and is a co-inventor of numerous patent applications in the drug development and life sciences fields. He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office, the U.S. District Court for the Eastern District of Pennsylvania, and the U.S. Court of Appeals for the Federal Circuit.

Corleen M. Roche Chief Financial Officer and Principal Accounting Officer
Age 60 · Total comp. $1,455,980.00 · As of 27 Apr 2026
Background

Ms. Corleen M. Roche joined the Company in August 2025 as our Chief Financial Officer. She has built an extensive track record throughout 30 years of experience in the biotech and life sciences industry, including executive financial leadership roles in publicly traded companies. Most recently she served as Chief Financial Officer of CG Oncology, a late-stage clinical biopharmaceutical company. Her previous roles included Chief Financial Officer of Immunome, U.S. Chief Financial Officer at Biogen, North America, Chief Financial Officer of CSL Behring, and various Chief Financial Officer roles within Sandoz and Wyeth and Pfizer. During her career, Ms. Roche developed and executed on financial strategies to prepare for commercial launches including ZARXIO, the first US approved biosimilar, GLATOPA, the world's first complex generic for multiple sclerosis and PREVNAR 13, a pneumococcal conjugate vaccine. She holds a B.S. in accountancy from Villanova University.

Dr. Raj K. Puri, M.D.,PhD Chief Regulatory Officer
Age 70 · Total comp. $1,341,778.00 · As of 27 Apr 2026
Background

Dr. Raj K. Puri, M.D. joined the Company in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri was promoted to Chief Regulatory Officer on November 22, 2024. He has decades of experience with the evaluation and regulation of advanced therapies, including cell and gene therapy, cancer vaccines and cellular immunotherapy. Dr. Puri previously spent 33 years working at the US Food and Drug Administration (FDA), including more than 19 years as the Director of the Division of Cellular and Gene Therapies (DCGT) in the Office of Tissues and Advanced Therapies at the Center for Biologics Evaluation and Research (CBER). He also participated and supervised development of FDA policies and guidance documents for advanced therapies. Dr. Puri was also a Chief of the Tumor Vaccines and Biotechnology Branch within DCGT and oversaw research programs of 13 principal investigators. As a Principal Investigator and throughout his career, Dr. Puri led cancer research and discovery of novel immunotherapies. He has published more than 300 research and review articles and participated in more than 220 speaking engagements at scientific, government, industry and professional societies. Dr. Puri has been granted numerous patents on his discoveries and many of his patents are licensed for further developments. While at FDA, Dr. Puri established seven Cooperative Research and Development Agreements (CRADAs) with different companies to develop his discoveries for cancer therapy. He has received numerous awards including the FDA Award of Merit, FDA CBER's Scientific Achievement Award, FDA Commissioner's Special Citations and the SITC Collaborator Award. Dr. Puri trained at the Surgery Branch of the National Cancer Institute (NCI), where he worked in the laboratory of Dr. Steven Rosenberg on adoptive immunotherapy approaches for cancer. Dr. Puri was also trained at the Mayo Clinic in Rochester, MN. He received an M.D. from the University of Juarez Medical School Institute of Biosciences and a Ph.D. in Medical Sciences from the Central Drug Research Institute, Lucknow, India.

Dr. Igor P. Bilinsky, PhD Chief Operating Officer
Age 53 · Total comp. $1,118,062.00 · As of 27 Apr 2026
Background

Dr. Igor P. Bilinsky, PhD joined the Company in March 2021 as our Chief Operating Officer. Dr. Bilinsky has more than 20 years of cumulative leadership experience through prior roles as Chief Executive Officer, Chief Operating Officer, and Chief Business Officer at companies within the life sciences industry. Prior to joining the Company, Dr. Bilinsky served as Chief Business Officer of Oncternal Therapeutics, Inc., from September 2019 to March 2021. From January 2017 to January 2019, Dr. Bilinsky served as Chief Operating Officer of AmpliPhi Biosciences, Inc., a biotechnology company developing targeted therapies for patients with life-threatening bacterial infections. From September 2015 to January 2017, he was General Manager, Immuno-Oncology, and Senior Vice President, Special Operations and Research Operations, at Ignyta, Inc., a biotechnology company focused on precision medicine in oncology that was acquired by Roche. His prior experience also includes senior executive roles at Vical and Halozyme Therapeutics, and Chief Executive Officer at Androclus Therapeutics. He also served as a principal in the healthcare practice of Boston Consulting Group. Dr. Bilinsky received a B.S. in physics from the Moscow Institute of Physics and Technology and a Ph.D. in physics from the Massachusetts Institute of Technology.

Dr. Michael Weiser,M.D.,PhD Independent Director
Age 63 · Total comp. $471,303.00 · As of 27 Apr 2026
Background

Dr. Michael Weiser,M.D.,PhD joined our Board of Directors in March 2018. He is the founder and has been a principal of Actin Biomed LLC since 2006. Actin Biomed is a healthcare investment firm focused on the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Biomed, Dr. Weiser was the Director of Research at Paramount BioCapital, Inc., a pharmaceutical development and healthcare investment firm. Dr. Weiser previously served as the chairman of the board of directors of Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company that was acquired by H. Lundbeck A/S in 2014, served on the board of directors of Ziopharm Oncology, Inc., a publicly traded biopharmaceutical company focused on immunotherapies in oncology and served on the board of directors of Emisphere Technologies, Inc., a pharmaceutical and drug delivery company. Dr. Weiser holds a B.A. in Psychology from the University of Vermont, received his M.D. from New York University School of Medicine and completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College.

Dr. Iain D. Dukes, D.Phil. Chairman of the Board
Age 67 · Total comp. $392,606.00 · As of 27 Apr 2026
Background

Dr. Iain D. Dukes, D.Phil joined our Board of Directors in August 2016 and was appointed Chairman of the Board on August 16, 2016. Dr. Dukes currently is a Venture Partner at OrbiMed Advisors LLC and the CEO of Eilean Therapeutics LLC. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories through May 2016. He joined Merck in August 2013. Prior to joining Merck, Dr. Dukes was Vice President of External Research & Development at Amgen, from August 2010 to August 2013. From 2007 to 2010, Dr. Dukes was the President and Chief Executive Officer, and a member of the board of directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. From 2000 to 2007, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, from 1990 to 1999, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. He also serves on the board of directors at Ikena Oncology and Traws Pharma, and privately held biotechnology companies NeRRe Therapeutics, Rathlin Therapeutics, ENYO Pharma, Feldan Therapeutics and Angiex Therapeutics. Dr. Dukes holds M.J. and Doctor of Philosophy degrees from the University of Oxford, a M.S. degree in Cardiovascular Studies from the University of Leeds and a Bachelor of Science degree in Pharmacology from the University of Bath.

Wayne P. Rothbaum Independent Director
Age 58 · Total comp. $240,000.00 · As of 27 Apr 2026
Background

Mr. Wayne P. Rothbaum joined our Board of Directors in June 2016. Mr. Rothbaum is president of Quogue Capital, a single-family office private equity fund focused on investing and supporting small to midcap life sciences companies. Mr. Rothbaum began his career at The Carson Group, a strategic consulting firm, where he managed its life sciences practice and boutique investment bank Evolution Capital. Following The Carson Group's sale to Thomson Reuters in 2001, Mr. Rothbaum founded Quogue Capital, through which he has founded and/or invested in numerous private and public life sciences companies. In 2012, Mr. Rothbaum co-founded and was the Executive Chairman of Acerta Pharma, a private life sciences company he later sold to AstraZeneca. Acerta's lead drug, Calquence (acalabrutinib) was approved by the FDA for mantle cell lymphoma in 2017 and chronic lymphocytic leukemia in 2020. In 2016, Mr. Rothbaum also co-founded Kartos Therapeutics following the in-license of an investigational MDM2 inhibitor from Amgen. More recently, in 2019, he co-founded Telios Pharma after licensing a novel targeted therapy from Merck KGaA to treat selected blood cancers and ophthalmology diseases. Additionally, Mr. Rothbaum has taken a leadership role in transforming the Company, restructuring and reorganizing our Board of Directors, senior management and overall clinical operations and strategy. Currently, Mr. Rothbaum is a board member and our largest shareholder. Mr. Rothbaum graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology and received his MA in international economics from The George Washington University. He is listed as an inventor on many scientific patents and is published in numerous medical journals, including The New England Journal of Medicine, The Lancet and the Journal of Clinical Oncology.

Ryan D. Maynard Independent Director
Age 56 · Total comp. $216,303.00 · As of 27 Apr 2026
Background

Mr. Ryan D. Maynard joined our Board of Directors in February 2015. Mr. Maynard is the Chief Financial Officer of Foghorn Therapeutics, Inc. Previously he served as Chief Financial Officer of Cara Therapeutics, Inc., a publicly-traded commercial-stage biopharmaceutical company, from September 2022 to 2025, and as the Chief Financial Officer of LetsGetChecked, from October 2019 to early 2022. Mr. Maynard was the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019. Until December 2017, he was the Executive Vice President and Chief Financial Officer of Rigel Pharmaceuticals, Inc., a public commercial-stage drug development company. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Rigel's Vice President of Finance and Acting Chief Financial Officer and became its Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999, he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young LLP. Mr. Maynard holds a B.S. in Commerce - Accounting from Santa Clara University.

Dr. Athena Countouriotis, M.D. Independent Director
Age 54 · Total comp. $216,303.00 · As of 27 Apr 2026
Background

Dr. Athena Countouriotis, M.D. joined our Board of Directors in June 2019. Dr. Countouriotis is the co-founder and Chief Executive Officer of Avenzo Therapeutics, a private biotechnology company focused on oncology. Previously she was the President and Chief Executive Officer and a board member of Turning Point Therapeutics from 2018 until it was acquired by Bristol-Myers Squibb in August 2022. Dr. Countouriotis has also served as the Chief Medical Officer for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led development of products for Pfizer and Bristol-Myers Squibb, including Sutent, Mylotarg, Bosulif and Sprycel. She also serves on the board of directors at BioMarin and Passage Bio, and privately held biotechnology companies Umoja Biopharma, Leal Therapeutics and Recludix Therapeutics. Dr. Countouriotis holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine. She received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology-Oncology Program.

Dr. Friedrich Graf Finckenstein, M.D. Chief Medical Officer
Age 59 · As of 27 Apr 2026
Background

Dr. Friedrich Graf Finckenstein, M.D. joined the Company in July 2019 as our Chief Medical Officer. Dr. Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, laboratory cancer research, and drug development in the biopharmaceutical industry. Prior to joining the Company, he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development in Basel, Switzerland, where he led all clinical development aspects in the Oncology Discovery and Translational Area, including the design and conduct of clinical trials, exploratory development studies and translational medicine, biomarker and personalized healthcare strategy. Prior to that, Dr. Graf Finckenstein held multiple clinical leadership roles at Bristol-Meyers Squibb Company, where he worked on an array of products from early clinical development to late stage, including key contributions to the approval of Opdivo in lung cancer. Dr. Graf Finckenstein has a medical degree from the University of Hamburg in Germany. He holds a German medical license, a pediatric board certification, and has conducted basic cancer research at the Ludwig Institute, San Diego Branch, the Children's Hospital Los Angeles and the University of Hamburg.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Discussion

No comments yet — be the first to weigh in on IOVA.

Sign in to join the discussion.

Scroll to Top